Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 746M | 4.7% |
| Gross Profit | 557M | 4.2% |
| Cost of Revenue | 188M | 44.5% |
| Operating expense | 443M | 3.8% |
| Net Income | 106M | 1% |
| EBITDA | 119M | 11.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 6.85B | 3.1% |
| Total Liabilities | 1.44B | 19.3% |
| Total Equity | 5.41B | 2.4% |
| Shares Outstanding | 191M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 221M | 86.5% |
| Cash from investing | -16M | 117.9% |
| Cash from financing | -499M | 4057.5% |
EPS
Financial Highlights for Biomarin Pharmaceutical in Q3 '24
Biomarin Pharmaceutical reported a revenue of 746M, which is a 4.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 557M, marking a -4.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 188M, a 44.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 443M, showing a -3.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 106M, showing a -1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 119M, showing a -11.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Biomarin Pharmaceutical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
